Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted M & A Cancer

QUOTED. 7 January. Kevin Thornal.

  • News

Executive Summary

Hologic announced its second acquisition this week and plans to spend $230m for the privately held diagnostics maker BioTheranostics Inc to align its broader corporate focus on women’s health. See what Hologic’s division president of diagnostics, Kevin Thornal, said about the buy-out here.

“Together with the Biotheranostics team, we can leverage our commercial capabilities and expertise in molecular diagnostics automation to accelerate growth, help physicians make more informed decisions and deliver more personalized treatment and better clinical outcomes for more women.” – Kevin Thornal, division president diagnostics, Hologic

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted M & A Cancer
Latest Headlines

Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold

It’s Official: FDA Drops Final Rule On LDTs

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

See All
UsernamePublicRestriction

Register

MT143293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By